XML 67 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration Agreements and Revenues - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 44,032 $ 33,174 $ 111,320 $ 248,603
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 11,935 0 162,517
Development Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 20,663 20,660 59,065 85,507
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 11,935 0 11,935
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 117,470
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 86 537 413 1,151
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 4,651 2,996 13,827 24,463
AstraZeneca Agreements [Member] | China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 706 19 1,300 19
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 33,112
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 15,220 $ 17,106 $ 43,525 $ 59,872